Pediatric Hypercalcemia Workup

  • Author: Ilene A Claudius, MD; Chief Editor: Stephen Kemp, MD, PhD   more...
 
Updated: Apr 3, 2012
 

Laboratory Studies

Overall, creating an all-encompassing algorithm for diagnosing the etiology of hypercalcemia is difficult. Clearly, the differential diagnosis widely varies on the basis of the child's age. Much of the laboratory workup should be guided by the history and physical examination. In infancy, a syndromic appearance of a child or dietary review may lead to very different diagnostic paths. If the history and physical examination yield no clear direction, a laboratory workup may reveal the diagnosis.

  • Initially, a physician must verify that the hypercalcemia is not a laboratory error. The most common reasons for falsely elevated serum calcium levels are hemoconcentration and elevated serum protein levels (eg, multiple myeloma). Acidosis increases the level of ionized calcium (but not total calcium) by changing plasma protein binding. A high intake of phosphate may also falsely elevate the serum calcium level.
  • In the neonate, in addition to calcium, determine serum protein, phosphate, and parathyroid hormone (PTH) levels as well as the levels of maternal calcium and maternal PTH. Serum calcium levels from other family members may also be helpful. In a baby with hypercalcemia, the serum PTH level should be lower than 10 pg/mL. A definitive diagnosis of hyperparathyroidism is confirmed by a PTH level higher than 50 pg/mL. In the situation of inappropriately normal or high PTH, consider hyperparathyroidism, familial hypocalciuric hypercalcemia, secondary hyperparathyroidism, and, rarely, malignancy. When PTH is suppressed, malignancy, granulomatous disease, iatrogenic causes, adrenal insufficiency, thyrotoxicosis, and vitamin D intoxication are possibilities.
  • Other laboratory findings that may be abnormal include sodium, potassium, and magnesium measurements. The reabsorption of these electrolytes is decreased in the proximal tubule, lowering their serum levels. Sensitivity to digitalis is increased, and a level should be assessed if the patient is taking digoxin. Perform BUN and creatinine tests to evaluate renal function, pancreatic enzyme tests to evaluate for pancreatitis, and stool hemoccult tests to evaluate for gastritis or a peptic ulcer if symptoms point toward these possibilities.
  • In childhood, the history and physical examination are extremely important. Inquire about symptoms or family history consistent with a multiple endocrine neoplasia (MEN) syndrome and perform molecular testing if appropriate. Consider the possibility of a malignancy, and direct the diagnostic evaluation toward that if symptoms or results from a CBC count point to this direction. Review the history and chest radiography for the possibility of granulomatous disease. Query about a history of signs or symptoms of thyrotoxicosis, and assess the level of thyroid-stimulating hormone (TSH) if indicated. Use history and creatinine clearance to eliminate renal failure. Ensure no medications, herbal preparations, or recent immobilizations are responsible. If this initial screen does not reveal the etiology, begin with serum PTH and phosphate, urine calcium, and serum bicarbonate measurements, and consider the other studies listed in the table below.
  • High PTH levels usually indicate primary hyperparathyroidism if the urine calcium–to–creatinine ratio is high and indicates familial hypocalciuric hypercalcemia if the urine calcium–to–creatinine ratio is low (confirm with DNA sequence analysis for CASR gene). Low PTH levels usually indicate hypervitaminosis D if 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels are high and indicate malignancy if they are low (confirm with high PTHrP level).
  • All laboratories have different reference-range values, examples of which are listed in the table below. Table 1. Normal Laboratory Values

    (Open Table in a new window)

    Laboratory Test Reference Range Normal Response to Increased Calcium
    Serum calcium8.5-10.2 mg/dLNA
    Ionized calcium1-1.3 mmol/LNA
    PTH (intact)10-55 pg/mL*Decrease
    Serum phosphateAge-dependentIncrease
    1,25-dihydroxyvitamin D36-108 pmol/LDecrease
    Alkaline phosphatase68-217 U/LNormal
    Urine calcium4 mg/kg/dIncrease
    Urine Ca/Cr ratioSee note†Increase
    Urine cAMP‡< 5 molDecrease
    *Note that 1 mmol/L equals 4 mg/dL. †In infants younger than 7 months, the reference range is less than 0.86; in infants aged 7-18 months, the reference range is less than 0.6. By age 6-7 years, the adult reference range of less than 0.21 is reached.‡The urine cAMP level generally parallels the PTH level.
  • Depending on the age of the patient and history obtained, consider all of the above tests.
  • When testing for hypervitaminosis D, assess the serum levels of 25-hydroxyvitamin D because they reflect the intake of vitamin D better than levels of 1,25-dihydroxyvitamin D. The exception to this is when 1,25-dihydroxyvitamin D is overingested or overproduced. Table 2. Additional Laboratory Values

    (Open Table in a new window)

    Condition Serum Phosphorus Serum Alkaline Phosphatase Urine Calcium Urine Phosphate PTH
    HyperparathyroidismLowNormal-highHigh*HighHigh
    Vitamin D excessNormal-highLowHighHigh
    MalignancyOften lowHigh † VariableHigh
    Granulomatous diseaseNormal-highNormal-highHighNormal
    Milk alkali syndromeNormal-highNormalNormalNormal
    FHHNormal or lowNormalLow (< 200mg/d)NormalLow
    *67% of the time



    † Except hematologic malignancies, in which alkaline phosphatase is normal



Next

Imaging Studies

  • Plain radiography may reveal demineralization, pathologic fractures, bone cysts, and bony metastases.
  • Renal imaging, ultrasonography, CT urography, or intravenous pyelography (IVP) may reveal evidence of calcifications or stones.
  • Perform ultrasonography of the parathyroid glands if hyperplasia or adenoma is a primary diagnosis. A sestamibi nuclear scan may be helpful in locating a parathyroid adenoma.
  • Other imaging tests may be necessary to exclude alternative diagnoses (eg, gallstone vs hypercalcemic pancreatitis) or to find a primary or associated malignancy if the laboratory tests or history produce suspicious findings.
Previous
Next

Other Tests

  • ECG
    • Shortened QT interval
    • Bradycardia
    • Coving of ST-T wave
    • Widened T wave
  • Ophthalmologic examination
    • Band keratopathy
    • Conjunctivitis
Previous
Next

Procedures

  • Localization of a parathyroid adenoma may be assisted by catheterization of the appropriate veins and measurements of PTH.
Previous
 
 
Contributor Information and Disclosures
Author

Ilene A Claudius, MD  Assistant Professor of Pediatrics, Division of Emergency Medicine, Children's Hospital, Los Angeles

Ilene A Claudius, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Coauthor(s)

Oved Fattal, MD  Staff Physician, Department of Pediatrics, Kaiser Permanente Medical Group

Oved Fattal, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Jon Nakamoto, MD  Consulting Staff, Department of Pediatric Endocrinology, Quest Diagnostics

Jon Nakamoto, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Pisit (Duke) Pitukcheewanont, MD  Associate Professor of Clinical Pediatrics, University of Southern California, Keck School of Medicine, Childrens Hospital Los Angeles

Pisit (Duke) Pitukcheewanont, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, American Medical Association, American Society for Bone and Mineral Research, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Thomas A Wilson, MD  Professor of Clinical Pediatrics, Chief and Program Director, Division of Pediatric Endocrinology, Department of Pediatrics, The School of Medicine at Stony Brook University Medical Center

Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Pediatric Endocrine Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London)  Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Merrily P M Poth, MD  Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences

Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD  Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. [Guideline] Hawley C, Elder G. Calcium. Westmead NSW (Australia): CARI - Caring for Australasians with Renal Impairment; 2005 Oct. [Full Text].

  2. Vezzoli G, Soldati L, Gambaro G. Roles of calcium-sensing receptor (CaSR) in renal mineral ion transport. Curr Pharm Biotechnol. Apr 2009;10(3):302-10. [Medline].

  3. Hsu YH, Chen HI. Acute respiratory distress syndrome associated with hypercalcemia without parathyroid disorders. Chin J Physiol. Dec 2008;51(6):414-8. [Medline].

  4. Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. Apr 1998;12(2):247-58. [Medline].

  5. Bennett MT, Sirrs S, Yeung JK, Smith CA. Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma. Dec 2005;46(12):1829-31. [Medline].

  6. Picolos MK, Lavis VR, Orlander PR. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf). Nov 2005;63(5):566-76. [Medline].

  7. Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S. Neridronic acid for the treatment of bone metabolic diseases. Expert Opin Drug Metab Toxicol. Oct 2009;5(10):1305-11. [Medline].

  8. Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V et al. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism in MEN1 patients. Clin Endocrinol. May 2008;Epub:[Medline].

  9. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. May 2008;66(5):839-47. [Medline].

  10. Oski F, DeAngelis CD, Feigin RD. Principles and Practice of Pediatrics. 2nd ed. 1994.

  11. Barkin RM, Capto GL, Jaffe DM, eds. Pediatric Emergency Medicine: Concepts and Clinical Practice. 2nd ed. 1997.

  12. Beer TM, Javle M, Lam GN, et al. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. Nov 1 2005;11(21):7794-9. [Medline].

  13. Behrman RE, Kliegman R, eds. Nelson Textbook of Pediatrics. 16th ed. WB Saunders Co; 2000.

  14. Benjamin RW, Moats-Staats BM, Calikoglu's A, Savendahl L, Chrysis D. Hypercalcemia in children. Pediatr Endocrinol Rev. Mar 2008;5(3):778-84. [Medline].

  15. Braverman LE. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 7th ed. 1997.

  16. Cheung M. Drugs used in paediatric bone and calcium disorders. Endocr Dev. 2009;16:218-232. [Medline].

  17. Cotran RS, Kumar V, Robbins SL. Pathologic Basis of Disease. 5th ed. 1994.

  18. Dambro MR. Griffith's 5 Minute Clinical Consult. Lippincott, Williams & Wilkins; 1999.

  19. Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. Nov 2005;27(11):1725-51. [Medline].

  20. Ellenhorn M. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. 1997.

  21. Feldman M, Sleisenger M, Scharschmidt BF, et al, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 6th ed. WB Saunders Co; 1997.

  22. Guyton AC. Human Physiology and Mechanisms of Disease. 5th ed. 1992.

  23. Isselbacher KJ, Braunwald E, Wilson JD. Harrison's Principles of Internal Medicine. 13th ed. 1994.

  24. Lee GR, Foerster J, Lukens J, eds. Wintrobe's Clinical Hematology. 10th ed. 1999.

  25. Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. Oct 1998;102(4 Pt 1):990-3. [Medline].

  26. Mosby. Mosby's GenRx. 10th ed. 1998.

  27. Mundy GR. Calcium Homeostasis: Hypercalcemia and Hypocalcemia. 1989.

  28. Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol. Oct 2008;23(10):1823-9. [Medline].

  29. Pizzo P, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 3rd ed. 1996.

  30. Poon G. Cinacalcet hydrochloride (Sensipar). Proc (Bayl Univ Med Cent). Apr 2005;18(2):181-4. [Medline].

  31. Rakel R. Robert Conn's Current Therapy. WB Saunders Co; 1999.

  32. Robinson DM, Scott LJ. Spotlight on paricalcitol in secondary hyperparathyroidism. Treat Endocrinol. 2005;4(3):185-6. [Medline].

  33. Rockwood C, ed. Rockwood and Greens' Fractures in Adults. 4th ed. 1996.

  34. Rodd C, Goodyer P. Hypercalcemia of the newborn: etiology, evaluation, and management. Pediatr Nephrol. Aug 1999;13(6):542-7. [Medline].

  35. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child. May 2005;90(5):494-9. [Medline].

  36. The Johns Hopkins Hospital. Harriet Lane Handbook: A Manual for Pediatric House Officers. 2000.

  37. Townsend C, ed. Sabiston Textbook of Surgery. 15th ed. 1997.

  38. Wallach J. Interpretation of Diagnostic Tests. 5th ed. 1992.

  39. Wilson J, ed. William's Textbook of Endocrinology. 1998.

  40. Yee YK, Chintalacharuvu SR, Lu J, Nagpal S. Vitamin D receptor modulators for inflammation and cancer. Mini Rev Med Chem. Aug 2005;5(8):761-78. [Medline].

  41. Zisman AL, Ghantous W, Schinleber P, et al. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. Nov-Dec 2005;25(6):591-5. [Medline].

Previous
Next
 
Investigations flowchart.
Table 1
Laboratory Test Reference Range Normal Response to Increased Calcium
Serum calcium8.5-10.2 mg/dLNA
Ionized calcium1-1.3 mmol/LNA
PTH (intact)10-55 pg/mL*Decrease
Serum phosphateAge-dependentIncrease
1,25-dihydroxyvitamin D36-108 pmol/LDecrease
Alkaline phosphatase68-217 U/LNormal
Urine calcium4 mg/kg/dIncrease
Urine Ca/Cr ratioSee note†Increase
Urine cAMP‡< 5 molDecrease
*Note that 1 mmol/L equals 4 mg/dL. †In infants younger than 7 months, the reference range is less than 0.86; in infants aged 7-18 months, the reference range is less than 0.6. By age 6-7 years, the adult reference range of less than 0.21 is reached.‡The urine cAMP level generally parallels the PTH level.
Table 2
Condition Serum Phosphorus Serum Alkaline Phosphatase Urine Calcium Urine Phosphate PTH
HyperparathyroidismLowNormal-highHigh*HighHigh
Vitamin D excessNormal-highLowHighHigh
MalignancyOften lowHigh † VariableHigh
Granulomatous diseaseNormal-highNormal-highHighNormal
Milk alkali syndromeNormal-highNormalNormalNormal
FHHNormal or lowNormalLow (< 200mg/d)NormalLow
*67% of the time



† Except hematologic malignancies, in which alkaline phosphatase is normal



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.